No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Chemicals - Specialty
Camlin Fine Sciences Limited, along with its subsidiaries, is actively engaged globally in the research, development, manufacturing, and distribution of specialized chemical products, functional ingredients, and additive blends. The company provides a comprehensive portfolio of shelf-life extension solutions, marketed under its Xtendra and NaSure brands. These solutions feature a variety of antioxidants, including synthetic compounds like Tertiary Butyl Hydroquinone, Butylated Hydroxy Anisole, and Ascorbyl palmitate, as well as plant-derived options such as mixed tocopherols, green tea extract, rosemary extract, and acerola extract. Furthermore, their offerings encompass mold inhibitors, preservatives, acidifiers, antibacterial agents, toxin binders, pellet binders, and growth promoters. Beyond shelf-life solutions, Camlin Fine Sciences also supplies aroma ingredients like vanillin and ethyl vanillin, pharmaceutical and nutraceutical substances sourced through fermentation and plant extraction, and performance chemicals including hydroquinone and catechol. Its diverse product range serves a wide array of industries, including food and beverage, pet food and animal nutrition, rendering, aquaculture, petrochemical, pharmaceutical, agrochemical, dyes and pigment, biofuel, aroma technical, fragrance, and flavor sectors. Founded in 1931 and based in Mumbai, India, the company operated as Camlin Fine Chemicals Limited until its rebranding to Camlin Fine Sciences Limited in August 2011.
www.camlinfs.comNo one on the platform currently holds CAMLINFINE.BO.
No tracked institution reports a position in CAMLINFINE.BO as of their last filing.
No one on the platform has traded CAMLINFINE.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 1.5% | — | — | — | ||
| Rev. Growth % | 3.4% | 7.9% | ||||
| Profit Margin % | 1.6% | -1.0% | -0.4% | |||
| Free Cash Flow Margin % | -1.9% | -1.7% | -3.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $21.2B | +18.5% | $6.60 | $6.46–$6.74 | — | 1 |
| 2028 | $24.6B | +16.4% | $10.03 | $9.97–$10.09 | — | 2 |
| 2029 | $31.8B | +29.0% | $21.90 | $21.43–$22.37 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $0.12 | $-0.60 | -600.0% |
| 2026-05-26 | $0.10 | $-1.00 | -1100.0% |
| 2026-02-13 | $0.60 | $-0.25 | -141.7% |
| 2025-11-10 | $0.90 | $-0.10 | -111.1% |
| 2025-08-08 | $1.45 | $0.20 | -86.2% |
| 2025-05-23 | $1.55 | $1.40 | -9.7% |
| 2025-02-14 | $0.20 | $0.30 | +53.5% |
| 2024-11-11 | $0.49 | $3.85 | +688.6% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| CAMLINFINE.BOCamlin Fine Sciences Limited | $97.25 | -1.97% | $18.6B | — |
| ADVENZYMES.BOAdvanced Enzyme Technologies Limited | $285.20 | -1.18% | $32.0B | — |
| ADVENZYMES.NSAdvanced Enzyme Technologies Limited | $285.75 | -0.68% | $32.0B | — |
| GRAUWEIL.BOGrauer & Weil (India) Limited | $72.75 | -0.52% | $33.0B | — |
| POCL.BOPondy Oxides And Chemicals Limited |
| $439.35 |
| +1.01% |
| $33.6B |
| — |
| POCL.NSPondy Oxides And Chemicals Limited | $440.30 | +1.15% | $33.6B | — |
| ROSSARI.BORossari Biotech Limited | $432.00 | -0.93% | $23.9B | — |
Source: Financial Modeling Prep · peers by sector/industry